JOP20250064A1 - نظام تجريع سوتوراسيب - Google Patents

نظام تجريع سوتوراسيب

Info

Publication number
JOP20250064A1
JOP20250064A1 JOJO/P/2025/0064A JOP20250064A JOP20250064A1 JO P20250064 A1 JOP20250064 A1 JO P20250064A1 JO P20250064 A JOP20250064 A JO P20250064A JO P20250064 A1 JOP20250064 A1 JO P20250064A1
Authority
JO
Jordan
Prior art keywords
sutouracip
dosing regimen
patient
sotorasib
bcrp
Prior art date
Application number
JOJO/P/2025/0064A
Other languages
Arabic (ar)
English (en)
Inventor
Panli Cardona
Brett E Houk
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JOP20250064A1 publication Critical patent/JOP20250064A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JOJO/P/2025/0064A 2022-09-30 2025-03-25 نظام تجريع سوتوراسيب JOP20250064A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263411789P 2022-09-30 2022-09-30
PCT/US2022/053130 WO2024072437A1 (en) 2022-09-30 2022-12-16 Sotorasib dosing regimen

Publications (1)

Publication Number Publication Date
JOP20250064A1 true JOP20250064A1 (ar) 2025-03-25

Family

ID=85158814

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2025/0064A JOP20250064A1 (ar) 2022-09-30 2025-03-25 نظام تجريع سوتوراسيب

Country Status (9)

Country Link
US (1) US20260083741A1 (https=)
EP (1) EP4593837A1 (https=)
JP (1) JP2025533334A (https=)
KR (1) KR20250079183A (https=)
AU (1) AU2022479909A1 (https=)
JO (1) JOP20250064A1 (https=)
MX (1) MX2025003741A (https=)
TW (1) TW202415380A (https=)
WO (1) WO2024072437A1 (https=)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023013557A (es) * 2021-05-18 2023-11-29 Amgen Inc Pauta posologica de sotorasib.

Also Published As

Publication number Publication date
TW202415380A (zh) 2024-04-16
US20260083741A1 (en) 2026-03-26
EP4593837A1 (en) 2025-08-06
AU2022479909A1 (en) 2025-02-06
KR20250079183A (ko) 2025-06-04
WO2024072437A1 (en) 2024-04-04
MX2025003741A (es) 2025-05-02
JP2025533334A (ja) 2025-10-06

Similar Documents

Publication Publication Date Title
Shanafelt et al. A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): a trial of the ECOG-ACRIN Cancer Research Group (E1912)
Kim et al. Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib
DePillis et al. Modeling cancer-immune responses to therapy
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
JOP20200292A1 (ar) Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان
EA201201186A1 (ru) ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
CY1113287T1 (el) Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα
Tao et al. Comparison of long-term survival and toxicity of cisplatin delivered weekly versus every three weeks concurrently with intensity-modulated radiotherapy in nasopharyngeal carcinoma
Keller et al. Outcomes in patients with mucosal melanomas
EA202092154A1 (ru) Комбинированная терапия
RU2013126036A (ru) Способ лечения опухолей
JOP20210125A1 (ar) إيلاسيسترانت بالاشتراك مع أبيماسيكليب عند النساء المصابات بسرطان الثدي
EP4393547A3 (en) Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
Lv et al. Cancer-associated fibroblasts: heterogeneity, tumorigenicity and therapeutic targets
EA201491352A1 (ru) Способ лечения рака груди
MX2023013557A (es) Pauta posologica de sotorasib.
JOP20250064A1 (ar) نظام تجريع سوتوراسيب
RU2014109999A (ru) Противоопухолевый агент и способ предсказания терапевтического эффекта для пациентов с раком ободочной и прямой кишки с мутацией гена kras
MX2021001606A (es) Tratamiento de la malignidades de las celulas b.
Lee et al. Subtype-specific radiation response and therapeutic effect of FAS death receptor modulation in human breast cancer
CR20220149A (es) Dosis para anticuerpos anti-triptasa
Oweida et al. Reconciling two opposing effects of radiation therapy: stimulation of cancer cell invasion and activation of anti-cancer immunity
JOP20240049A1 (ar) سوتوراسيب وجسم مضاد لـ egfr لعلاج سرطان يشمل طفرة kras g12c
Yin et al. Incidence of second malignancies of chronic myeloid leukemia during treatment with tyrosine kinase inhibitors
Sparano et al. P258: Factors associated with distant recurrence (DR) risk in patients (pts) with HR+/HER2− early breast cancer (EBC): a machine learning (ML) model–based analysis using real-world (RW) data